A detailed history of First Trust Advisors LP transactions in Neurocrine Biosciences Inc stock. As of the latest transaction made, First Trust Advisors LP holds 544,321 shares of NBIX stock, worth $67.1 Million. This represents 0.06% of its overall portfolio holdings.

Number of Shares
544,321
Previous 433,537 25.55%
Holding current value
$67.1 Million
Previous $59.7 Million 5.0%
% of portfolio
0.06%
Previous 0.06%

Shares

29 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 13, 2024

BUY
$114.58 - $153.15 $12.7 Million - $17 Million
110,784 Added 25.55%
544,321 $62.7 Million
Q2 2024

Aug 13, 2024

SELL
$130.86 - $143.19 $12.2 Million - $13.3 Million
-93,045 Reduced 17.67%
433,537 $59.7 Million
Q1 2024

May 13, 2024

SELL
$130.4 - $143.74 $8.36 Million - $9.22 Million
-64,143 Reduced 10.86%
526,582 $72.6 Million
Q4 2023

Feb 13, 2024

BUY
$106.07 - $132.76 $13.5 Million - $16.9 Million
127,085 Added 27.41%
590,725 $77.8 Million
Q3 2023

Nov 13, 2023

SELL
$94.02 - $117.1 $6.32 Million - $7.87 Million
-67,244 Reduced 12.67%
463,640 $52.2 Million
Q2 2023

Aug 14, 2023

SELL
$89.53 - $104.87 $12.8 Million - $15 Million
-143,132 Reduced 21.24%
530,884 $50.1 Million
Q1 2023

May 15, 2023

BUY
$94.11 - $123.02 $28,044 - $36,659
298 Added 0.04%
674,016 $68.2 Million
Q4 2022

Feb 09, 2023

SELL
$106.72 - $127.06 $9.72 Million - $11.6 Million
-91,049 Reduced 11.91%
673,718 $80.5 Million
Q3 2022

Nov 14, 2022

BUY
$92.03 - $107.81 $17.8 Million - $20.8 Million
193,015 Added 33.76%
764,767 $81.2 Million
Q2 2022

Aug 12, 2022

SELL
$75.79 - $100.07 $5.21 Million - $6.88 Million
-68,707 Reduced 10.73%
571,752 $55.7 Million
Q1 2022

May 13, 2022

BUY
$72.45 - $94.81 $3.15 Million - $4.12 Million
43,447 Added 7.28%
640,459 $60 Million
Q4 2021

Feb 08, 2022

SELL
$79.65 - $106.22 $6.47 Million - $8.63 Million
-81,261 Reduced 11.98%
597,012 $50.8 Million
Q3 2021

Nov 15, 2021

BUY
$86.18 - $99.03 $2.65 Million - $3.04 Million
30,718 Added 4.74%
678,273 $65.1 Million
Q2 2021

Aug 16, 2021

SELL
$89.43 - $102.27 $576,912 - $659,743
-6,451 Reduced 0.99%
647,555 $63 Million
Q1 2021

May 14, 2021

BUY
$87.57 - $119.4 $1.4 Million - $1.9 Million
15,949 Added 2.5%
654,006 $63.6 Million
Q4 2020

Feb 02, 2021

SELL
$86.91 - $108.33 $17.9 Million - $22.3 Million
-206,232 Reduced 24.43%
638,057 $61.2 Million
Q3 2020

Nov 05, 2020

SELL
$96.16 - $135.15 $1.23 Million - $1.72 Million
-12,747 Reduced 1.49%
844,289 $81.2 Million
Q2 2020

Jul 22, 2020

SELL
$85.09 - $130.36 $6.92 Million - $10.6 Million
-81,342 Reduced 8.67%
857,036 $105 Million
Q1 2020

May 06, 2020

BUY
$75.11 - $113.76 $22.2 Million - $33.7 Million
296,167 Added 46.12%
938,378 $81.2 Million
Q4 2019

Feb 03, 2020

SELL
$86.8 - $118.57 $6.8 Million - $9.3 Million
-78,397 Reduced 10.88%
642,211 $69 Million
Q3 2019

Nov 04, 2019

SELL
$83.82 - $101.5 $46.7 Million - $56.5 Million
-557,092 Reduced 43.6%
720,608 $64.9 Million
Q2 2019

Jul 30, 2019

BUY
$72.24 - $91.27 $14.1 Million - $17.8 Million
194,643 Added 17.97%
1,277,700 $108 Million
Q1 2019

May 09, 2019

SELL
$69.31 - $91.53 $15 Million - $19.8 Million
-216,398 Reduced 16.65%
1,083,057 $95.4 Million
Q4 2018

Feb 07, 2019

BUY
$68.32 - $124.36 $19 Million - $34.6 Million
278,598 Added 27.29%
1,299,455 $92.8 Million
Q3 2018

Oct 25, 2018

BUY
$98.88 - $125.85 $4.07 Million - $5.18 Million
41,186 Added 4.2%
1,020,857 $126 Million
Q2 2018

Aug 02, 2018

BUY
$75.3 - $105.99 $3.93 Million - $5.53 Million
52,200 Added 5.63%
979,671 $96.2 Million
Q1 2018

Apr 23, 2018

BUY
$75.88 - $92.43 $5.66 Million - $6.9 Million
74,636 Added 8.75%
927,471 $76.9 Million
Q4 2017

Feb 08, 2018

BUY
$58.53 - $77.59 $4.11 Million - $5.44 Million
70,150 Added 8.96%
852,835 $66.2 Million
Q3 2017

Oct 24, 2017

BUY
$47.97 - $61.28 $37.5 Million - $48 Million
782,685
782,685 $48 Million

Others Institutions Holding NBIX

About NEUROCRINE BIOSCIENCES INC


  • Ticker NBIX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Drug Manufacturers—Specialty & Generic
  • Shares Outstandng 95,639,296
  • Market Cap $11.8B
  • Description
  • Neurocrine Biosciences, Inc. discovers, develops, and markets pharmaceuticals for neurological, endocrine, and psychiatric disorders. The company's portfolio includes treatments for tardive dyskinesia, Parkinson's disease, endometriosis, and uterine fibroids, as well as clinical programs in various therapeutic areas. Its lead asset is INGREZZA, ...
More about NBIX
Track This Portfolio

Track First Trust Advisors LP Portfolio

Follow First Trust Advisors LP and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of First Trust Advisors LP, based on Form 13F filings with the SEC.

News

Stay updated on First Trust Advisors LP with notifications on news.